All In Biotech

NDA 020451 · Pinnacle Biolgs

Photofrin

Porfimer Sodium · Injection

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jan 1, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Dec 27, 1995

Approved uses

4

Original approval plus efficacy supplements

Registered trials

33

7 Phase 3, 0 recruiting

FAERS reports

341

313 serious, 74 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 28, 2026.

PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy Endobronchial Cancer ( 1.2 ) Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC High-Grade Dysplasia in Barrett’s Esophagus ( 1.3 ) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE) patients who do not undergo esophagectomy 1.1 Esophageal Cancer PHOTOFRIN ® is indicated for the palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their healthcare provider, cannot be satisfactorily treated with Nd:YAG laser therapy. 1.2 Endobronchial Cancer PHOTOFRIN is indicated for the treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated. PHOTOFRIN is indicated for the reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC. 1.3 High-Grade Dysplasia in Barrett’s Esophagus PHOTOFRIN is indicated for the ablation of high-grade dysplasia in Barrett’s esophagus patients who do not undergo esophagectomy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 8, 2008 Supplement 19 · Efficacy LabelLetter
  • Dec 22, 1998 Supplement 3 · Efficacy Letter
  • Jan 9, 1998 Supplement 2 · Efficacy Letter
  • Dec 27, 1995 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
  • PHOTOFRIN · PORFIMER SODIUM 75MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Porfimer" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use72
  • cholangitis42
  • oesophageal stenosis28
  • dyspnoea19
  • hypotension19
  • sepsis15
  • photosensitivity reaction14
  • pneumonia14
  • post procedural complication14
  • swelling face13
  • deep vein thrombosis12
  • fatigue11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
200517
200633
200731
20087
200916
201018
20115
201252
201322
201412
201530
201623
201715
20187
201910
20201
20218
20224
20235
20247
20257
20265

Recalls

1 FDA enforcement reports for this application.

  • Feb 10, 2014 · Class III · Terminated

    Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 94 on PubMed

Sponsor: Pinnacle Biolgs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.